Antimicrobial Resistance and Therapeutic Discovery Training Program

抗菌素耐药性和治疗发现培训计划

基本信息

  • 批准号:
    10019072
  • 负责人:
  • 金额:
    $ 24.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

The challenge of drug-resistant microbes requires that a new generation of basic scientists be broadly trained and educated in a triad of equally important sub-disciplines of anti-infective research: i.) mechanisms of antimicrobial resistance (AMR); ii.) antimicrobial discovery and development; and iii.) vaccinology to prevent or treat infections for which antimicrobial therapies are absent or becoming ineffectual due to AMR. The continued success of the Antimicrobial Resistance and Therapeutic Discovery Training Program (ARTDTP) of Emory University will help to ensure that a cadre of investigators will be available in the future to combat the global health problem of AMR. This need for future scientists in anti-infective research is an international priority given the reduced number of new, effective antimicrobials (antibiotics and antivirals) that have entered clinical practice in the past two decades and the difficulty often faced by physicians in treating certain infections because of AMR or the lack of effective therapeutics. Thus, the objective of the competitive renewal of ARTDTP is to provide high quality training to a select group of highly motivated graduate students for careers as independent investigators. Towards that end, ARTDTP will select five Ph.D. candidates yearly from four graduate programs within the Graduate Division of Biological and Biomedical Sciences and the Department of Chemistry for a two-year period of training in the areas of AMR and therapeutic discovery through chemical or immunologic-based strategies. ARTDTP faculty members who will serve as the pool of preceptors for trainees are highly collaborative and span the university with academic appointments in basic science and clinical departments of the School of Medicine and Emory College of Arts and Sciences. Educational training will consist of a course of study and programmatic events in sub-disciplines that emphasize research and education in AMR and drug discovery or vaccine development. ARTDTP will be governed by an Executive Committee and evaluated bi-yearly by an external Advisory Committee and by trainees after completion of their two-year program of training. Recruitment of under-represented minority students (URMS) from local and national colleges and universities will be a priority for ARTDTP and specific initiatives coupled with university-based programs will be employed to maximally train URMS. In addition to training in the sub-disciplines of anti- infective research ARTDTP trainees will receive education in the essential concepts of rigor, reproducibility and ethics that are needed for careers in the biological and biomedical fields. Upon completion of training and receipt of the Ph.D. degree, ARTDTP trainees will be ready to assume post-doctoral positions in academia, government or industry that continue their interests developed through the training experience provided by our T32 pre-doctoral program.
抗药性微生物的挑战要求新一代基础科学家接受广泛的培训 并在抗感染研究的三个同等重要的子学科中接受教育:i.)机制 抗微生物剂抗性(AMR); ii.)抗菌剂的发现和开发;和iii.)疫苗学以预防或 治疗由于AMR而缺乏抗菌治疗或变得无效的感染。继续 埃默里大学抗菌素耐药性和治疗发现培训计划(ARTDTP)的成功 联合国大学将帮助确保今后有一支调查骨干队伍, AMR的健康问题。这种对未来科学家在抗感染研究方面的需求是国际优先考虑的问题。 进入临床实践的新的、有效的抗菌药物(抗生素和抗病毒药)数量减少 在过去的二十年里,由于AMR,医生在治疗某些感染时经常面临困难, 或者缺乏有效的治疗方法。因此,ARTDTP竞争性更新的目标是提供高质量的 高质量的培训,以高度积极性的研究生作为独立的研究人员的职业选择组。 为此,ARTDTP将选择五位博士。候选人每年从四个研究生课程内, 生物和生物医学科学研究生部和化学系,为期两年 在AMR和通过化学或免疫学为基础的治疗发现领域的培训, 战略布局ARTDTP教师谁将作为培训人员的导师池是高度 协作和跨越大学与学术任命的基础科学和临床部门, 医学院和埃默里文理学院。教育培训将包括 强调AMR研究和教育的子学科的学习课程和计划活动 和药物发现或疫苗开发。ARTDTP将由执行委员会管理, 每两年由外部咨询委员会进行评估,并由学员在完成两年培训后进行评估。 培训计划。从地方和国家招收代表性不足的少数民族学生 学院和大学将是ARTDTP的优先事项,并将具体倡议与基于大学的 计划将被用来最大限度地培训URMS。除了在反恐怖主义的次级学科中进行培训外, 感染性研究ARTDTP学员将接受严格性、可重复性、 以及生物学和生物医学领域职业所需的道德。培训结束后 并获得博士学位学位,ARTDTP学员将准备承担博士后职位, 学术界、政府或工业界继续通过培训经验发展他们的兴趣 由我们的T32博士预科课程提供。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Maurice Shafer其他文献

William Maurice Shafer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Maurice Shafer', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10514632
  • 财政年份:
    2020
  • 资助金额:
    $ 24.27万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10091811
  • 财政年份:
    2020
  • 资助金额:
    $ 24.27万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10337023
  • 财政年份:
    2020
  • 资助金额:
    $ 24.27万
  • 项目类别:
Function and regulation of the intrinsic antibiotic resistome of Neisseria gonorrhoeae
淋病奈瑟菌内在抗生素耐药性的功能和调控
  • 批准号:
    10646403
  • 财政年份:
    2019
  • 资助金额:
    $ 24.27万
  • 项目类别:
Function and regulation of the intrinsic antibiotic resistome of Neisseria gonorrhoeae
淋病奈瑟菌内在抗生素耐药性的功能和调控
  • 批准号:
    10426304
  • 财政年份:
    2019
  • 资助金额:
    $ 24.27万
  • 项目类别:
Function and regulation of the intrinsic antibiotic resistome of Neisseria gonorrhoeae
淋病奈瑟菌内在抗生素耐药性的功能和调控
  • 批准号:
    10201478
  • 财政年份:
    2019
  • 资助金额:
    $ 24.27万
  • 项目类别:
Function and regulation of the intrinsic antibiotic resistome of Neisseria gonorrhoeae
淋病奈瑟菌内在抗生素耐药性的功能和调控
  • 批准号:
    9982208
  • 财政年份:
    2019
  • 资助金额:
    $ 24.27万
  • 项目类别:
Gonococci: Genetics of Resistance to PMN Proteins
淋球菌:PMN 蛋白抗性遗传学
  • 批准号:
    9040074
  • 财政年份:
    2015
  • 资助金额:
    $ 24.27万
  • 项目类别:
Antimicrobial Resistance and Therapeutic Discovery Training Program
抗菌素耐药性和治疗发现培训计划
  • 批准号:
    8737434
  • 财政年份:
    2014
  • 资助金额:
    $ 24.27万
  • 项目类别:
Antimicrobial Resistance and Therapeutic Discovery Training Program
抗菌素耐药性和治疗发现培训计划
  • 批准号:
    8852534
  • 财政年份:
    2014
  • 资助金额:
    $ 24.27万
  • 项目类别:

相似海外基金

Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network (CanDoIt)
智能乳腺癌诊断和监测治疗反应训练网络(CanDoIt)
  • 批准号:
    EP/Y03693X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Research Grant
Non invasive methods to accelerate the development of injectable therapeutic depots
非侵入性方法加速注射治疗储库的开发
  • 批准号:
    EP/Z532976/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Research Grant
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Research Grant
Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: CPS: Medium: Automating Complex Therapeutic Loops with Conflicts in Medical Cyber-Physical Systems
合作研究:CPS:中:自动化医疗网络物理系统中存在冲突的复杂治疗循环
  • 批准号:
    2322534
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Standard Grant
Uncovering the antimicrobial and antibiotic potentiating mechanism of acesulfame-K and maximising its topical therapeutic potential.
揭示安赛蜜的抗菌和抗生素增强机制并最大限度地发挥其局部治疗潜力。
  • 批准号:
    MR/Y001354/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Research Grant
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Collaborative R&D
In vivo polymer synthesis for therapeutic application via glycosylated artificial metalloenzymes
通过糖基化人工金属酶进行体内聚合物合成用于治疗应用
  • 批准号:
    24K08629
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ヒトiPS細胞由来唾液腺幹細胞を用いた再生治療におけるTherapeutic time windowの同定
使用人类 iPS 细胞来源的唾液腺干细胞鉴定再生治疗的治疗时间窗
  • 批准号:
    24K12975
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.27万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了